The Center for Healthcare Supply Chain Research serves as the knowledge partner and research arm of the Healthcare Distribution Management Association. The Center is committed to serving the healthcare industry by providing research and education on priority patient safety and healthcare supply chain issues. The Center is a non-profit charitable organization.

 

 
Latest News

See You in Dallas!

Learn more about the event
Register now!

Don’t miss the Center’s first annual Specialty Pharmaceutical Seminar on January 31st-February 1st, 2012 in Dallas, Texas. This education and networking event features expert speakers on hot topics in the fastest-growing segment of the pharmaceutical market, including a look at growth drivers, the rise of oral agents in specialty care, how biosimilars will affect the specialty supply chain, and much more.

2011 Updated Role of the Distributors Report Now Available

Purchase your copy today!
Read the press release
View the Role of the Distributors webinar:
Flash | MP4

Building on research studies completed in 2004 and 2007, this industry assessment, conducted by Booz & Company, analyzes the dynamics affecting the healthcare supply chain in the past four years, and provides a qualitative and quantitative view of the unique services and value traditional distributors provide to the U.S. healthcare system. This study, which used interviews with executives from across the healthcare supply chain, documents the value distributors deliver, as well as describes how pharmaceuticals flow through the supply chain, and sheds light on changes the industry has seen since the Center’s 2007 report.

Order the 2011 Specialty Pharmaceuticals: Facts, Figures and Trends Today!

Purchase your copy today!
Click here for an order form
View the table of contents
Read the press release

The 2011 Specialty Pharmaceuticals: Facts, Figures and Trends benchmarking report is now available. This report, in its third year, provides primary survey data from distributors and manufacturers of specialty pharmaceutical products to show trends and changes in the fastest-growing segment of the marketplace. Featuring data on market characteristics, finance, operations, growth in the oncology area, changes with the aging population and much more, this report provides a means for companies to benchmark their business processes, learn about the specialty segment and foresee future opportunities and challenges for this market. 


2011-2012 HDMA Factbook Now Available

Read the Press Release
Purchase Your Copy Today!
Order your Kindle edition from Amazon.com
View the Table of Contents
Download an order form
Sponsorship Opportunities

Now in its 83rd edition, the 2011–2012 HDMA Factbook is the healthcare distribution industry’s most comprehensive and reliable source of industry performance data. This easy-to-use reference guide features more than 150 robust data tables based on original survey data as well as secondary sources from leading industry healthcare industry organizations. 

The 2011-2012 HDMA Factbook is now available in electronic Kindle format through Amazon.com or the traditional hard-copy format through the HDMA Marketplace.

This year’s edition is produced with support from Boehringer Ingelheim Pharmaceuticals, Inc.; RDC-Rochester Drug Cooperative, Inc.; Endo Pharmaceuticals; TEVA Pharmaceuticals USA; and AstraZeneca Pharmaceuticals LP.
Publications

Specialty Pharmaceuticals and the Role of the Specialty Distributor

Specialty Pharmaceuticals and the Role of the Specialty Distributor is the newest in a series of publications completed by the Center for Healthcare Supply Chain Research providing information on the fastest-growing segment of the pharmaceutical industry. This research report, prepared by Arthur D. Little, provides detailed findings on the cost savings that specialty distributors provide to the healthcare industry, using an economic analysis that includes distributor replacement scenarios. The study outlines how specialty pharmaceuticals come to market; explains the services, processes and efficiencies provided by specialty distributors; and highlights future trends to expect in this market. Expand your library on the specialty pharmaceutical market today!

Read the press release
View the table of contents
Purchase your copy
Download an order form

  

The Center Publishes New Report on Risk Evaluation and Mitigation Strategies (REMS)

The Center for Healthcare Supply Chain Research recently released Assessing the Impact of Risk Evaluation and Mitigation Strategies (REMS) Requirements on the Pharmaceutical Supply Chain, the first comprehensive research study analyzing the impact of REMS programs across the healthcare supply chain. Produced in collaboration with Campbell Alliance Group, Inc., the study outlines the current REMS landscape, evaluates the impact of these requirements on key supply chain stakeholders, illustrates the challenges the industry faces, examines economic considerations, assesses two program case studies and highlights opportunities for future program enhancements. The research provides recommendations on how to improve REMS in the future, as well as insights that are helpful to anyone seeking to understand the potential impact of REMS on the pharmaceutical supply chain.

Read the press release
Read our article for APhA
Read our Pharmaceutical Commerce article
View the table of contents
Purchase your copy
Download an order form

Browse All Research Projects and Publications

LoJack® Supply Chain Integrity provides integrated solutions for supply chain protection that includes shared supply chain intelligence and analytics, covert cargo tracking, monitoring, and recovery services. The LoJack® SCI solutions feature proactive alert based security and increased visibility across all modes of transportation with clear chain of custody management utilizing active sensing of the cargo’s environment while in-transit.

LoJack® Supply Chain Integrity was a generous sponsor of the Center’s 2nd Supply Chain Security Seminar on May 17-18th, 2011 in Alexandria, VA.  This event brings together the top security and logistics professionals in the industry each year to discuss current issues and advancements in safeguarding pharmaceutical products.  Learn more about LoJack SCI.

REMS

As of December 23, 2012, there are 105 pharmaceutical products that require Risk Evaluation and Mitigation Strategies (REMS). This number was 179 in March 2011, but from April 14, 2011 to the present date, FDA has ruled to remove several medications from their medication guide-only requirements.

32 products require Medication Guides

18 products requires a Communication Plan only

24 products require Medication Guides and Communication Plans

5 products require Medication Guides and Elements to Assure Safe Use

2 products require Communication Plans, Elements to Assure Safe Use, and Implementation Systems

14 products require Medication Guides, Elements to Assure Safe Use, and Implementation Systems

10 products require Medication Guides, Communication Plans, Elements to Assure Safe Use, and Implementation Systems

To learn more about the impact of REMS on the supply chain, order the Center’s REMS publication today!

  HDMA  |  HOME  |  CONTACT US  |  SITE MAP Privacy and Terms of Use  |  ® , Center for Healthcare Supply Chain Research  |  Phone: 703.885.0256